Erlotinib in Advanced Non-small Cell Lung Cancer: Efficacy and Safety Findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Erlotinib in Advanced Non-small Cell Lung Cancer: Efficacy and Safety Findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Study

Published:2010-10 Issue:10 Volume:5 Page:1616-1622
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Reck Martin,van Zandwijk Nico,Gridelli Cesare,Baliko Zoltan,Rischin Danny,Allan Simon,Krzakowski Maciej,Heigener David

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference21 articles.

1. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005

2. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR. 21;Bezjak;J Clin Oncol,2006

3. Gefitinib therapy for non-small cell lung cancer;Birnbaum;Curr Treat Options Oncol,2005

4. Practical management of patients with non-small-cell lung cancer treated with gefitinib;Shah;J Clin Oncol,2005

5. Erlotinib: optimizing therapy with predictors of response?;Goodin;Clin Cancer Res,2006

Cited by 119 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Simultaneous UHPLC-PDA Method Development and Validation for Quantification of Quercetin and Erlotinib in Liquid Crystalline Nanoparticle Formulation and Pharmacokinetic Study;Chromatographia;2024-08-08

2. Impact of CD151 overexpression on prognosis and therapy in non‐small cell lung cancer patients lacking EGFR mutations;Cell Proliferation;2024-07-09

3. Multidrug-Resistant Profiles in Non-Small Cell Lung Carcinoma Patient-Derived Cells: Implications for Personalized Approaches with Tyrosine Kinase Inhibitors;Cancers;2024-05-23

4. Treatment of Non-Small Cell Lung Cancer with Atypical EGFR Mutations;Current Treatment Options in Oncology;2023-12

5. Ocular side effects of oncological therapies: Review;Archivos de la Sociedad Española de Oftalmología (English Edition);2023-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3